Compare CarMax, Inc (KMX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Novartis AG — how do they compare? CarMax, Inc trades at $55.91 (market cap $7.93B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 36.6× CarMax, Inc's market cap, and Novartis AG pays a 3.17% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | NVS | |
|---|---|---|
Market Cap | $7.93B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $63.53 | $168.62 |
52-Week Low | $30.88 | $113.50 |
Enterprise Value | $26.44B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $57.61, up 0.49% on the day, with a bullish technical outlook supported by moving averages and a strong ADX signal. Recent Q1 2026 earnings beat expectations, driven by cost control and revenue growth, though net income margins remain thin at 0.84%. The company's four-pillar strategy focuses on volume, digital sales, and efficiency, with positive analyst coverage highlighting value and momentum potential.
The stock's upside is supported by operational improvements and insider buying, but risks include high debt levels, margin pressure, and a pending legal investigation. Analyst consensus is cautious with a $48.91 price target below the current price, suggesting limited near-term upside amid execution risks.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
